title: Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma.
abstract: Evidence from cytogenetics, multipoint linkage analyses of familial melanoma, and loss of heterozygosity studies of familial and sporadic melanomas support localization of a melanoma susceptibility or tumor suppressor gene at chromosomal region 9p21-23. Recently, the inhibitor of cyclin-dependent kinase 4 (CDK4I; also known as p16INK4, multiple tumor suppressor 1, or CDKN2 gene) has been mapped to 9p21 and shown to be mutated or deleted in a large fraction of cell lines derived from many tumor types, including melanoma, suggesting that this gene could be a melanoma suppressor gene. In order to test for somatic mutations in the CDK4I gene in tumors, DNAs from 30 surgically resected melanomas of both cutaneous and uveal origins were sequenced. No mutations were detected in the coding region of the CDK4I gene, while mutations or deletions were detected in 60% (9 of 15) of the cultured melanoma cell line DNAs. Among presumptive familial cases, nine of which were members of families with one or two other documented melanoma cases, no germline mutations were detected by sequence analysis. A deletion in the second exon of the CDK4I gene was found in one germline allele of a familial melanoma patient from a family with eight affected first degree relatives. These results not only support the suggestion that the CDK4I gene is a familial malignant melanoma gene, they also suggest the presence of another suppressor gene locus within 9p21 which is the target of loss of heterozygosity in sporadic melanomas.
authors.affiliation: Jefferson Cancer Center, Jefferson Medical College, Philadelphia, Pennsylvania 19107.
authors.forename: M
authors.initials: M
authors.lastname: Ohta
authors.forename: H
authors.initials: H
authors.lastname: Nagai
authors.forename: M
authors.initials: M
authors.lastname: Shimizu
authors.forename: D
authors.initials: D
authors.lastname: Rasio
authors.forename: D
authors.initials: D
authors.lastname: Berd
authors.forename: M
authors.initials: M
authors.lastname: Mastrangelo
authors.forename: A D
authors.initials: AD
authors.lastname: Singh
authors.forename: J A
authors.initials: JA
authors.lastname: Shields
authors.forename: C L
authors.initials: CL
authors.lastname: Shields
authors.forename: C M
authors.initials: CM
authors.lastname: Croce
mesh_terms: D001483:Base Sequence; D002899:Chromosomes, Human, Pair 9; D051358:Cyclin-Dependent Kinase 4; D018844:Cyclin-Dependent Kinases; D004252:DNA Mutational Analysis; D005091:Exons / Q000235:genetics*; D017353:Gene Deletion; D016147:Genes, Tumor Suppressor / Q000235:genetics*; D006801:Humans; D008545:Melanoma / Q000201:enzymology / Q000235:genetics*; D008969:Molecular Sequence Data; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000235:genetics; D011518:Proto-Oncogene Proteins; D012878:Skin Neoplasms / Q000201:enzymology / Q000235:genetics*; D014604:Uveal Neoplasms / Q000201:enzymology / Q000235:genetics*
chemical_list: D011518:Proto-Oncogene Proteins; D017346:Protein Serine-Threonine Kinases; C495900:CDK4 protein, human; D051358:Cyclin-Dependent Kinase 4; D018844:Cyclin-Dependent Kinases